The TRILOGY ACS (Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes) PFT (VerifyNow P2Y12 assay) sub-study showed that even with a more potent P2Y12 inhibitor like prasugrel, which resulted in lower platelet reactivity when compared to clopidogrel (median 64; interquartile range (IQR), 33–128 P2Y12 reaction unit (PRU) vs. 200; IQR, 141–260 PRU; p < 0.001), there was no significant difference in clinical outcomes (cardiovascular death, myocardial infarction and stroke) at 30 months (17.2% vs. 18.9%, p = 0.29). The gene discussed is P2RY12; the disease is acute coronary syndrome.